Filing Details
- Accession Number:
- 0000950170-24-030479
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-12 21:56:20
- Reporting Period:
- 2024-03-08
- Accepted Time:
- 2024-03-12 21:56:20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1818794 | Dyne Therapeutics Inc. | DYN | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1528826 | T Joshua Brumm | 1560 Trapelo Road Waltham MA 02451 | Ceo & President | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-03-08 | 153,931 | $5.54 | 708,316 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-03-08 | 209,412 | $5.54 | 917,728 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-08 | 202,238 | $25.30 | 715,490 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-03-08 | 160,670 | $26.72 | 554,820 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-03-08 | 435 | $27.38 | 554,385 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-03-11 | 50,000 | $5.54 | 604,385 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-11 | 40,072 | $25.42 | 564,313 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-03-11 | 9,928 | $26.10 | 554,385 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-03-11 | 7,769 | $26.12 | 546,616 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-03-11 | 8,618 | $25.93 | 537,998 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2024-03-08 | 153,931 | $0.00 | 153,931 | $5.54 |
| Common Stock | Stock option (right to buy) | Disposition | 2024-03-08 | 209,412 | $0.00 | 209,412 | $5.54 |
| Common Stock | Stock option (right to buy) | Disposition | 2024-03-11 | 50,000 | $0.00 | 50,000 | $5.54 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2030-07-30 | No | 4 | M | Direct | |
| 133,269 | 2030-07-30 | No | 4 | M | Direct | |
| 83,269 | 2030-07-30 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.18, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.49, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.75, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.01 to $26.10, inclusive.
- Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.22 to $26.18, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.68 to $26.05, inclusive.
- Includes 513,913 unvested RSUs.
- The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.
- The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020.
Billionaire Hedge Funds
